SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Deal History & Licensing Activity
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) is a large pharma headquartered in UK. Over the past three years, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) has been involved in 12 licensing and acquisition transactions, with a primary focus on Oligonucleotides (7 deals).
Deals (12mo)
8
Active Trials
0
Top Modality
Oligonucleotides
Focus Area
Infectious Disease
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving SmithKline Beecham Corporation and Glaxo Group Limited (GSK) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Nuvalent precision kinase inhibitor portfolio | GSK | Small Molecules | Unknown | acquisition | Jun 9, 2026 |
| HRS-9821 | GSK | Small Molecules | Unknown | option | Jun 3, 2026 |
| JNJ-3989 | Arrowhead | Oligonucleotides | Unknown |
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Pipeline Focus
Therapeutic areas and modalities where SmithKline Beecham Corporation and Glaxo Group Limited (GSK) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches SmithKline Beecham Corporation and Glaxo Group Limited (GSK)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About SmithKline Beecham Corporation and Glaxo Group Limited (GSK) Licensing & Deal Activity
SmithKline Beecham Corporation and Glaxo Group Limited (GSK) is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 12 deals over the past three years, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for SmithKline Beecham Corporation and Glaxo Group Limited (GSK) include Infectious Disease (7 deals and trials), Oncology (3 deals and trials), Other (3 deals and trials), and Cardiovascular (2 deals and trials). In terms of modality, SmithKline Beecham Corporation and Glaxo Group Limited (GSK) has shown particular interest in oligonucleotides, small molecules, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for SmithKline Beecham Corporation and Glaxo Group Limited (GSK) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against SmithKline Beecham Corporation and Glaxo Group Limited (GSK)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.